The first thing that comes to mind when thinking about gene therapy is its ability to replace a missing gene or correct a defective one. A gene therapy vector can also be used to insert instructions for cells to begin making a therapeutic protein. Regenxbio Inc.’s RGX-314, which uses an adeno-associated virus (AAV) vector to deliver an inhibitor of vascular endothelial growth factor (VEGF), is one such example.
In a move to boost its eye care portfolio following the acquisition of Allergan plc, AbbVie Inc. licensed rights to Regenxbio’s RGX-314, which is in a pivotal trial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?